Last reviewed · How we verify
Anesthesia induction with propofol
Anesthesia induction with propofol is a GABA-A receptor positive allosteric modulator Small molecule drug developed by Daegu Catholic University Medical Center. It is currently in Phase 3 development for Induction of general anesthesia in adults and children, Maintenance of general anesthesia, Sedation in intensive care unit patients. Also known as: Induction of anesthesia by intravenous infusion of propofol.
Propofol is a rapid-acting intravenous anesthetic that enhances inhibitory GABA-A receptor signaling in the central nervous system to produce sedation and unconsciousness.
Propofol is used for anesthesia induction. As a positive allosteric modulator of the GABA-A receptor, propofol exerts its anesthetic effects.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anesthesia induction with propofol |
|---|---|
| Also known as | Induction of anesthesia by intravenous infusion of propofol |
| Sponsor | Daegu Catholic University Medical Center |
| Drug class | GABA-A receptor positive allosteric modulator |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and hyperpolarizing neuronal membranes. This results in rapid onset of general anesthesia suitable for induction of anesthesia in surgical and procedural settings. The drug has a short duration of action due to rapid redistribution and metabolism.
Approved indications
- Induction of general anesthesia in adults and children
- Maintenance of general anesthesia
- Sedation in intensive care unit patients
Common side effects
- Hypotension
- Respiratory depression
- Injection site pain
- Bradycardia
- Apnea
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery (NA)
- Propofol Versus Sevoflurane Anesthesia on the Intraocular Pressure and Hemodynamics in Patient Undergoing Cyclophotocoagulation (NA)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia
- Study Comparing Local/ MAC Anesthesia in Lumbar Decompression (EARLY_PHASE1)
- Deep Versus Moderate Neuromuscular Blocking (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anesthesia induction with propofol CI brief — competitive landscape report
- Anesthesia induction with propofol updates RSS · CI watch RSS
- Daegu Catholic University Medical Center portfolio CI
Frequently asked questions about Anesthesia induction with propofol
What is Anesthesia induction with propofol?
How does Anesthesia induction with propofol work?
What is Anesthesia induction with propofol used for?
Who makes Anesthesia induction with propofol?
Is Anesthesia induction with propofol also known as anything else?
What drug class is Anesthesia induction with propofol in?
What development phase is Anesthesia induction with propofol in?
What are the side effects of Anesthesia induction with propofol?
What does Anesthesia induction with propofol target?
Related
- Drug class: All GABA-A receptor positive allosteric modulator drugs
- Target: All drugs targeting GABA-A receptor
- Manufacturer: Daegu Catholic University Medical Center — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for Induction of general anesthesia in adults and children
- Indication: Drugs for Maintenance of general anesthesia
- Indication: Drugs for Sedation in intensive care unit patients
- Also known as: Induction of anesthesia by intravenous infusion of propofol
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing